WARNING
Cardiovascular Risk
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL TRIALS).
- MOBIC tablets/oral suspension is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Gastrointestinal Risk
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
|
| |
MOBIC SUMMARY
Mobic®
(meloxicam)
Tablets 7.5 mg and 15 mg
and
Mobic®
(meloxicam)
Oral Suspension 7.5 mg/5 mL
MOBIC® (meloxicam), an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow tablet contains meloxicam 7.5 mg or 15 mg for oral administration.
MOBIC is indicated for relief of the signs and symptoms of osteoarthritis.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Mobic (Meloxicam)
Analgesia after feline ovariohysterectomy under midazolam-medetomidine-ketamine
anaesthesia with buprenorphine or butorphanol, and carprofen or meloxicam: a
prospective, randomised clinical trial. [2012]
One hundred female cats undergoing routine ovariohysterectomy under
midazolam-medetomidine-ketamine anaesthesia were included in a blinded,
randomised, prospective clinical study to compare postoperative analgesia
produced by four analgesic drug combinations given preoperatively (n = 25 per
group)...
A randomized, single-blind comparison of the efficacy and tolerability of
hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the
knee. [2012]
The aim of this study was to prospectively evaluate the efficacy and tolerability
of hyaluronic acid (HA) and meloxicam for the treatment of knee pain due to
Kashin-Beck disease (KBD). A total of 162 patients with KBD-based knee pain were
randomly assigned to treatment with a 3-week course of HA (n = 80) and a 12-week
course of meloxicam (n = 82)...
Clinical evaluation of meloxicam versus ketoprofen in cats suffering from painful acute locomotor disorders. [2011.04]
The aim of this study was to evaluate the efficacy and palatability of meloxicam 0.5mg/ml oral suspension, compared to ketoprofen tablets in cats suffering from painful acute locomotor disorders. This single blinded, positively-controlled, randomised, multicentre trial involved 121 client owned cats...
Evaluation of subcutaneous and oral administration of robenacoxib and meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs. [2011.02]
OBJECTIVE: To assess efficacy and tolerability of robenacoxib for control of pain and inflammation in dogs undergoing orthopedic surgery. ANIMALS: 140 client-owned dogs.
Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. [2011.02]
The pharmacokinetics and analgesic effect of the nonsteroidal anti-inflammatory drug meloxicam (0.5 mg/kg) in goats were investigated. In a randomized, cross-over design the pharmacokinetic parameters were investigated in adult goats (n = 8) after single intravenous and oral administration... Plasma cortisol and glucose concentrations did not differ between the two groups.
Clinical Trials Related to Mobic (Meloxicam)
The BE Study of Meloxicam GSK 15mg (BA/BE 250/12-117176) [Not yet recruiting]
It is a randomized, balanced, open label, crossover, two period, two treatment, two
sequence, single dose, oral bioequivalence study of Meloxicam GSK 15 mg tablets manufactured
by Savipharm J. S.Cc, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH &
Co. KG Binger Str. 173, 5521 Ingelheim am Rhein, Germany, in healthy, adult, human male
subjects under fed condition. It is a pivotal study to demonstrate the bioequivalence of
Meloxicam GSK 15 mg tablets manufactured by Savipharm J. S.C, Vietnam and Mobic® 15 mg
tablets of Boehringer Ingelheim Pharma GmbH & Co. KG Binger Str. 173, 5521 Ingelheim am Rhein,
Germany, in healthy adult human male subjects under fed condition.
This study will enroll 28 healthy adult human male subjects
Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15Â mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg
tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x
15 mg) dose administration under fed conditions.
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15Â mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg
tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x
15 mg) dose administration under fasting conditions.
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee [Recruiting]
This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will
also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis
in this population.
Study of a COX-2 Inhibitor for Prevention of Ovulation [Recruiting]
In this study the investigators propose to evaluate a COX-2 inhibitor(meloxicam) to assess
its effect on follicular development and find out if this regimen delays or blocks ovulation
while maintaining ovarian cyclicity. The investigators intend to administer 15 mg or 30 mg
of meloxicam per day for 18 days starting on day 5 after onset of menses during 3 continuous
cycles. The 3 treatment cycles will be preceded and followed by control cycles with no
treatment. Ovulation or lack there of will be monitored by transvaginal ultrasound
examinations (TVUs), estradiol, luteinizing hormone (LH), and progesterone levels in
multiple blood samples in each cycle. The investigators will recruit a total of 56 women.
Each woman will be randomly assigned to 1 of the 2 dose regimens of meloxicam, with 28 women
assigned to each of the 2 dose regimens. Participating women will demonstrate an ovulatory
cycle before starting meloxicam treatment and will be protected from pregnancy by prior
sterilization.
Reports of Suspected Mobic (Meloxicam) Side Effects
Anaemia (27),
Drug Ineffective (19),
Dyspnoea (18),
Renal Failure Acute (17),
Arthralgia (16),
Pain (15),
Diplopia (15),
Abdominal Pain (14),
Constipation (14),
Decreased Appetite (14), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 26 ratings/reviews, Mobic has an overall score of 6.15. The effectiveness score is 6.69 and the side effect score is 7.54. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Mobic review by 63 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Arthritis |
| Dosage & duration: | | 20 mg taken once a day for the period of Months |
| Other conditions: | | Asthma |
| Other drugs taken: | | Serevent, Singulaire | | |
Reported Results |
| Benefits: | | Pain reduction, increased mobility and range of motion. The difference between how I feel with and without Mobic is astonishing. Unfortunately, if I take this drug for more than six months straight, it begins to lose effectiveness. Thus, I now save it for situations where I absolutely need it: travel, sports, etc. |
| Side effects: | | None. My only complaint is that it loses effectiveness when taken over a period of time. |
| Comments: | | Took once a day, always with food to protect my stomach. |
|
| | Mobic review by 65 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Ineffective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | arthritis/knee pain |
| Dosage & duration: | | 7.5mg taken i daily for the period of 2 years to date |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | quite effective without the adverse effects of aspirin, naproxin etc.
because of the reported side effects of cox2 meds i take as little as possible to maintain a reletively comfortable exixtence |
| Side effects: | | only side effect was sore tummy on the odd occasion i took it without food |
| Comments: | | i take 1x 7.5 tablet every other day plus omega 3/6/9 and halibut liver oil caps and walk as much as possible. I only resort to 1 tablet daily if knee is really bad. 15mg daily and i am pain free but i am not prepared to risk the side effects on an otherwise healthy body |
|
| | Mobic review by 80 year old male patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Marginally Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | severe back pain |
| Dosage & duration: | | 7.5 mg daily taken bid for the period of not started |
| Other conditions: | | polymyalgia rheumatica |
| Other drugs taken: | | prednisone requip klonopin prilosec zoloft | | |
Reported Results |
| Benefits: | | None yet |
| Side effects: | | None...YET |
| Comments: | | After reading these reviews, I'm afraid of even starting this drug even with doctor's Rx. of t.5 mg daily. Occasionally very effective but below average I think. Why run tge risk of some of the horrible side effects, e.g. stomach surgery. No thanks. I'll take my prednisone!! |
|
|
|
Page last updated: 2013-02-10
|
